TNF in the era of immune checkpoint inhibitors: friend or foe?
Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care. However, their use is complicated by adverse effects known as immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis....
Uloženo v:
| Vydáno v: | Nature reviews. Rheumatology Ročník 17; číslo 4; s. 213 - 223 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Nature Publishing Group
01.04.2021
|
| Témata: | |
| ISSN: | 1759-4790, 1759-4804, 1759-4804 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care. However, their use is complicated by adverse effects known as immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis. ICI-induced inflammatory arthritis is distinguished from other irAEs by its persistence and requirement for long-term treatment. TNF inhibitors are commonly used to treat inflammatory diseases such as rheumatoid arthritis, spondyloarthropathies and inflammatory bowel disease, and have also been adopted as second-line agents to treat irAEs refractory to glucocorticoid treatment. Experiencing an irAE is associated with a better antitumour response after ICI treatment. However, whether TNF inhibition can be safely used to treat irAEs without promoting cancer progression, either by compromising ICI therapy efficacy or via another route, remains an open question. In this Review, we discuss clinical and preclinical studies that address the relationship between TNF, TNF inhibition and cancer. The bulk of the evidence suggests that at least short courses of TNF inhibitors are safe for the treatment of irAEs in patients with cancer undergoing ICI therapy. Data from preclinical studies hint that TNF inhibition might augment the antitumour effect of ICI therapy while simultaneously ameliorating irAEs. |
|---|---|
| AbstractList | Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care. However, their use is complicated by adverse effects known as immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis. ICI-induced inflammatory arthritis is distinguished from other irAEs by its persistence and requirement for long-term treatment. TNF inhibitors are commonly used to treat inflammatory diseases such as rheumatoid arthritis, spondyloarthropathies and inflammatory bowel disease, and have also been adopted as second-line agents to treat irAEs refractory to glucocorticoid treatment. Experiencing an irAE is associated with a better antitumour response after ICI treatment. However, whether TNF inhibition can be safely used to treat irAEs without promoting cancer progression, either by compromising ICI therapy efficacy or via another route, remains an open question. In this Review, we discuss clinical and preclinical studies that address the relationship between TNF, TNF inhibition and cancer. The bulk of the evidence suggests that at least short courses of TNF inhibitors are safe for the treatment of irAEs in patients with cancer undergoing ICI therapy. Data from preclinical studies hint that TNF inhibition might augment the antitumour effect of ICI therapy while simultaneously ameliorating irAEs.Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care. However, their use is complicated by adverse effects known as immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis. ICI-induced inflammatory arthritis is distinguished from other irAEs by its persistence and requirement for long-term treatment. TNF inhibitors are commonly used to treat inflammatory diseases such as rheumatoid arthritis, spondyloarthropathies and inflammatory bowel disease, and have also been adopted as second-line agents to treat irAEs refractory to glucocorticoid treatment. Experiencing an irAE is associated with a better antitumour response after ICI treatment. However, whether TNF inhibition can be safely used to treat irAEs without promoting cancer progression, either by compromising ICI therapy efficacy or via another route, remains an open question. In this Review, we discuss clinical and preclinical studies that address the relationship between TNF, TNF inhibition and cancer. The bulk of the evidence suggests that at least short courses of TNF inhibitors are safe for the treatment of irAEs in patients with cancer undergoing ICI therapy. Data from preclinical studies hint that TNF inhibition might augment the antitumour effect of ICI therapy while simultaneously ameliorating irAEs. Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care. However, their use is complicated by adverse effects known as immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis. ICI-induced inflammatory arthritis is distinguished from other irAEs by its persistence and requirement for long-term treatment. TNF inhibitors are commonly used to treat inflammatory diseases such as rheumatoid arthritis, spondyloarthropathies and inflammatory bowel disease, and have also been adopted as second-line agents to treat irAEs refractory to glucocorticoid treatment. Experiencing an irAE is associated with a better antitumour response after ICI treatment. However, whether TNF inhibition can be safely used to treat irAEs without promoting cancer progression, either by compromising ICI therapy efficacy or via another route, remains an open question. In this Review, we discuss clinical and preclinical studies that address the relationship between TNF, TNF inhibition and cancer. The bulk of the evidence suggests that at least short courses of TNF inhibitors are safe for the treatment of irAEs in patients with cancer undergoing ICI therapy. Data from preclinical studies hint that TNF inhibition might augment the antitumour effect of ICI therapy while simultaneously ameliorating irAEs. Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care. However, their use is complicated by adverse effects known as immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis. ICI-induced inflammatory arthritis is distinguished from other irAEs by its persistence and requirement for long-term treatment. TNF inhibitors are commonly used to treat inflammatory diseases such as rheumatoid arthritis, spondyloarthropathies and inflammatory bowel disease, and have also been adopted as second-line agents to treat irAEs refractory to glucocorticoid treatment. Experiencing an irAE is associated with a better antitumour response after ICI treatment. However, whether TNF inhibition can be safely used to treat irAEs without promoting cancer progression, either by compromising ICI therapy efficacy or via another route, remains an open question. In this Review, we discuss clinical and preclinical studies that address the relationship between TNF, TNF inhibition and cancer. The bulk of the evidence suggests that at least short courses of TNF inhibitors are safe for the treatment of irAEs in patients with cancer undergoing ICI therapy. Data from preclinical studies hint that TNF inhibition might augment the antitumour effect of ICI therapy while simultaneously ameliorating irAEs.TNF inhibitors are used to treat various immune-related adverse events caused by immune checkpoint inhibitors (ICIs). However, whether TNF inhibition compromises the anticancer efficacy of ICI therapy is unknown. This Review discusses the relationship between TNF, TNF inhibition and cancer. |
| Author | Chen, Allen Y Wolchok, Jedd D Bass, Anne R |
| Author_xml | – sequence: 1 givenname: Allen Y surname: Chen fullname: Chen, Allen Y organization: Department of Medicine, Weill Cornell Medicine, New York, NY, USA – sequence: 2 givenname: Jedd D orcidid: 0000-0001-6718-2222 surname: Wolchok fullname: Wolchok, Jedd D organization: Human Oncology and Pathogenesis Program, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA – sequence: 3 givenname: Anne R orcidid: 0000-0002-3225-8351 surname: Bass fullname: Bass, Anne R email: bassa@hss.edu, bassa@hss.edu organization: Department of Medicine, Weill Cornell Medicine, New York, NY, USA. bassa@hss.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33686279$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkE1LAzEYhINU7If-AQ8S8OJlNdkku288WKRYFYpe6nnZjzc0tZvUZPfgv3fF9uJpBuZhGGZKRs47JOSSs1vOBNxFyRXIhKU8YezXyRMy4bnSiQQmR0efazYm0xi3jGUyA31GxkJkkKW5npCH9duSWke7DVIMJfWG2rbtHdJ6g_Xn3lvXDfnGVrbzId5TEyy6hvpAjcf5OTk15S7ixUFn5GP5tF68JKv359fF4yqpMwFdojjnGgBMrcEYXYNAbRCGGU1VKpblDKXJGq6ZaUqZG24wrSUAE4hVY5iYkZu_3n3wXz3GrmhtrHG3Kx36Phap1FoAqDQf0Ot_6Nb3wQ3rilQxpXIBkg_U1YHqqxabYh9sW4bv4viM-AHmD2Wa |
| CitedBy_id | crossref_primary_10_37349_ei_2025_1003196 crossref_primary_10_3389_fphar_2023_1169327 crossref_primary_10_1007_s10792_021_02058_8 crossref_primary_10_3390_cancers17050732 crossref_primary_10_1136_ard_2022_222451 crossref_primary_10_1038_s41584_022_00841_0 crossref_primary_10_1177_10781552231167824 crossref_primary_10_1038_s41584_021_00640_z crossref_primary_10_1158_2326_6066_CIR_24_0387 crossref_primary_10_3390_jcm12041630 crossref_primary_10_3390_ijms23105486 crossref_primary_10_3389_fphar_2022_990445 crossref_primary_10_3390_pharmaceutics14020440 crossref_primary_10_3390_v15030777 crossref_primary_10_1002_anbr_202300061 crossref_primary_10_3390_biology11101481 crossref_primary_10_1016_j_jgo_2024_102071 crossref_primary_10_1002_ctd2_171 crossref_primary_10_1002_cmdc_202500258 crossref_primary_10_1111_imj_70183 crossref_primary_10_2147_JIR_S282600 crossref_primary_10_3389_fimmu_2022_804597 crossref_primary_10_1016_j_heliyon_2024_e37376 crossref_primary_10_14309_ajg_0000000000001983 crossref_primary_10_3390_jpm13091347 crossref_primary_10_1136_jitc_2022_005718 crossref_primary_10_3389_fimmu_2024_1328145 crossref_primary_10_3390_antib11030046 crossref_primary_10_1016_j_ejca_2024_114172 crossref_primary_10_3389_fonc_2022_933407 crossref_primary_10_1016_j_rdc_2024_02_007 crossref_primary_10_1038_s41584_021_00641_y crossref_primary_10_3390_biomedicines10102610 crossref_primary_10_1016_S2665_9913_24_00379_5 crossref_primary_10_1097_WCO_0000000000001259 crossref_primary_10_1038_s41698_023_00380_1 crossref_primary_10_11569_wcjd_v33_i7_513 crossref_primary_10_1038_s41568_025_00858_z crossref_primary_10_1186_s12891_025_08563_6 crossref_primary_10_1016_j_autrev_2021_102892 crossref_primary_10_1016_j_jaut_2022_102828 crossref_primary_10_1038_s41582_024_01001_6 crossref_primary_10_1002_adtp_202300302 crossref_primary_10_5415_apallergy_0000000000000146 crossref_primary_10_1016_j_mattod_2024_08_006 crossref_primary_10_2147_BTT_S252575 crossref_primary_10_1038_s41388_024_03194_y crossref_primary_10_1016_j_cyto_2022_155948 crossref_primary_10_3390_cancers17172765 crossref_primary_10_1016_j_bioactmat_2024_05_030 crossref_primary_10_3390_ph16111610 crossref_primary_10_1093_rheumatology_keaf356 crossref_primary_10_3390_cancers17030390 crossref_primary_10_3389_fimmu_2022_1064033 crossref_primary_10_3390_molecules27144572 crossref_primary_10_3389_fimmu_2022_947341 crossref_primary_10_3389_fonc_2022_928390 crossref_primary_10_1093_cei_uxaf050 crossref_primary_10_3389_fimmu_2022_835997 crossref_primary_10_1186_s40364_024_00580_2 crossref_primary_10_1016_j_ymthe_2022_12_009 crossref_primary_10_3390_cancers14102460 crossref_primary_10_1016_j_biomaterials_2023_122247 crossref_primary_10_1038_s41392_024_01868_3 crossref_primary_10_1016_j_toxlet_2022_08_003 crossref_primary_10_1186_s12885_023_11383_3 crossref_primary_10_1038_s41571_021_00597_8 crossref_primary_10_3390_cancers15113041 crossref_primary_10_1007_s12282_024_01618_x crossref_primary_10_1016_j_cpt_2023_08_001 crossref_primary_10_3389_fimmu_2025_1523854 crossref_primary_10_1097_MCP_0000000000000800 crossref_primary_10_1016_j_immuni_2025_02_017 crossref_primary_10_3389_fcell_2021_717601 crossref_primary_10_1007_s00395_024_01046_0 crossref_primary_10_1016_j_canlet_2023_216182 crossref_primary_10_1158_0008_5472_CAN_24_0932 crossref_primary_10_1038_s41584_021_00653_8 crossref_primary_10_3390_cancers13133306 crossref_primary_10_3390_cancers17050880 crossref_primary_10_1016_j_beha_2025_101625 crossref_primary_10_1038_s41392_023_01364_0 crossref_primary_10_1002_advs_202416265 crossref_primary_10_1016_j_biopha_2024_117551 crossref_primary_10_1016_j_scib_2024_07_001 crossref_primary_10_1007_s00393_025_01677_1 crossref_primary_10_3390_cancers15072084 crossref_primary_10_1016_j_colsurfb_2025_115094 crossref_primary_10_1016_j_rdc_2024_01_001 crossref_primary_10_1007_s00262_023_03384_9 crossref_primary_10_1158_1078_0432_CCR_22_3653 crossref_primary_10_3389_fimmu_2022_883733 crossref_primary_10_1136_ard_2023_223885 crossref_primary_10_3390_cancers16101892 crossref_primary_10_3389_fimmu_2024_1394123 crossref_primary_10_3390_cancers15051629 crossref_primary_10_3390_ijms26125892 crossref_primary_10_3390_ph17080991 crossref_primary_10_1016_j_ejca_2024_114028 crossref_primary_10_1016_j_chembiol_2025_07_006 crossref_primary_10_1016_j_drudis_2021_09_024 crossref_primary_10_1080_17425255_2022_2043849 crossref_primary_10_3390_biomedicines10061334 crossref_primary_10_1016_j_pccm_2023_08_002 crossref_primary_10_3389_fimmu_2023_1167975 crossref_primary_10_1038_s41584_021_00654_7 crossref_primary_10_3390_ijms26083506 crossref_primary_10_3389_fimmu_2022_955812 crossref_primary_10_3389_fonc_2022_871390 |
| ContentType | Journal Article |
| Copyright | Springer Nature Limited 2021. |
| Copyright_xml | – notice: Springer Nature Limited 2021. |
| DBID | CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1038/s41584-021-00584-4 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1759-4804 |
| EndPage | 223 |
| ExternalDocumentID | 33686279 |
| Genre | Journal Article Review Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- .XZ 0R~ 29M 39C 53G 70F 7X7 88E 8FE 8FH 8FI 8FJ AARCD AAWTL AAWYQ AAYZH ABAWZ ABFSG ABJNI ABLJU ABUWG ACGFS ACSTC ADBBV AENEX AEZWR AFANA AFFVI AFHIU AFKRA AFSHS AGAYW AHBCP AHMBA AHOSX AHSBF AHWEU AIBTJ AIXLP ALFFA ALMA_UNASSIGNED_HOLDINGS ALPWD ARMCB ATHPR AXYYD BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CCPQU CGR CUY CVF DB5 EBS ECM EE. EIF EJD EXGXG F5P FQGFK FSGXE FYUFA HCIFZ HMCUK HZ~ IAO IHR IHW INH INR ITC LK8 M1P M7P NFIDA NNMJJ NPM ODYON OVD PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO RNR RNT RNTTT S70 SHXYY SIXXV SNYQT SOJ TAOOD TBHMF TDRGL TEORI TSG UKHRP 3V. 7XB 8FK AGSTI AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c638t-51119888fc98ff9c83e9fe8336dba50670e4f6d190fda47f1fe2c48803eebdf03 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 124 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000626388100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1759-4790 1759-4804 |
| IngestDate | Thu Oct 02 19:26:47 EDT 2025 Tue Oct 07 06:58:29 EDT 2025 Mon Jul 21 06:01:08 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c638t-51119888fc98ff9c83e9fe8336dba50670e4f6d190fda47f1fe2c48803eebdf03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-6718-2222 0000-0002-3225-8351 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/8366509 |
| PMID | 33686279 |
| PQID | 2505573841 |
| PQPubID | 2041929 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2499388527 proquest_journals_2505573841 pubmed_primary_33686279 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-01 |
| PublicationDateYYYYMMDD | 2021-04-01 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London |
| PublicationTitle | Nature reviews. Rheumatology |
| PublicationTitleAlternate | Nat Rev Rheumatol |
| PublicationYear | 2021 |
| Publisher | Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group |
| References | 34103724 - Nat Rev Rheumatol. 2021 Aug;17(8):505-506 34226728 - Nat Rev Rheumatol. 2021 Sep;17(9):577-578 34103723 - Nat Rev Rheumatol. 2021 Aug;17(8):505 34226729 - Nat Rev Rheumatol. 2021 Sep;17(9):577 |
| References_xml | – reference: 34226729 - Nat Rev Rheumatol. 2021 Sep;17(9):577 – reference: 34103724 - Nat Rev Rheumatol. 2021 Aug;17(8):505-506 – reference: 34226728 - Nat Rev Rheumatol. 2021 Sep;17(9):577-578 – reference: 34103723 - Nat Rev Rheumatol. 2021 Aug;17(8):505 |
| SSID | ssj0064689 |
| Score | 2.6128619 |
| SecondaryResourceType | review_article |
| Snippet | Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced cancer and have emerged as a pillar of standard cancer care.... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 213 |
| SubjectTerms | Adverse events Arthritis Arthritis - chemically induced Arthritis - immunology Cancer Drug Interactions Drug Synergism Drug-Related Side Effects and Adverse Reactions - immunology Glucocorticoids Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immunotherapy - methods Inflammation - chemically induced Inflammation - drug therapy Inflammatory bowel diseases Intestine Neoplasms - drug therapy Neoplasms - immunology Patients Rheumatoid arthritis Risk Assessment Safety Spondyloarthropathy TNF inhibitors Tumor necrosis factor Tumor Necrosis Factor Inhibitors - adverse effects Tumor Necrosis Factor Inhibitors - pharmacology Tumor Necrosis Factor Inhibitors - therapeutic use Tumor Necrosis Factor-alpha - immunology |
| Title | TNF in the era of immune checkpoint inhibitors: friend or foe? |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33686279 https://www.proquest.com/docview/2505573841 https://www.proquest.com/docview/2499388527 |
| Volume | 17 |
| WOSCitedRecordID | wos000626388100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NT9swFH8aBU27jDHG1lEqI3G1SGMntjmAAFFxIaoQSL1VTuKnRUhJaQt_P--l6Tixyy6-2LKs52e_7_cDOIlT9HmcJzJClUqtlZHeJkGSKMR4xB3BHLZgEybL7HTqJp3DbdmlVW7-xPajLpuCfeSnLKoTo6weXcyfJaNGcXS1g9DYgm3ukqDa1L3J5idOddpC4JGEdOxBirqimUjZ0yUJLqslJygwsp6W-mMVsxU1493_PeQ3-NopmeJyzRV78CnU3-HzXRdG34fzh2wsqlqQ8ifCwosGRcV1IkHQFRZP86aqVzT_p8orBuM5E8jdkEvRLAQ24eIHPI5vHq5vZQekIAt6XitJStXIkamLhbOIrrAqOAxWqbTMfcKVOkFjWpJugKXXBkcY4oJftgohLzFSB9Crmzr8ApE7k5RsycbeaZ8mLioi2gt96p3yHvsw2FBm1r2G5eydLH04_jtNfMzBCV-H5oXWkOmlrE1i04efa-rP5uuGGzM6KBlexv3-9-aH8CVuL5TzagbQWy1ewhHsFK-rarkYwpaZmna0Q9i-uskm98OWXWjMJndvibzDqw |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoALUJ4LhRoJjlazthPbSG1VAatWbVccFmlvwUk8IkJKlt0tiD_Fb2Qmm21P7a0Hzo5GVubzPOyZ-QDeqQxDoYpUJqgzaYy2Mrg0SnKFqIY8EcxjRzZhx2M3nfovG_B33QvDZZVrm9gZ6qot-Y58l111arUzw4PZT8msUfy6uqbQWMHiJP75TSnbYu_4E-n3vVKjz5OPR7JnFZAlYW0pKcKgRNs5LL1D9KXT0WN0WmdVEVJuW4kGs4ocJVbBWBxiVCXDXMdYVJhoknsLbpMdt1xCZqcXCV5mso5yjzyy5xurpG_SSbTbXZCjdEZyQQQz-Rlprg5pO9c2evi__ZRH8KAPosXhCvVbsBGbx3D3rC8TeAL7k_FI1I2g4FbEeRAtipr7YKIgiJY_Zm3dLGn9e13UTDb0QSBPe65EOxfYxoOn8PVGdv8MNpu2iS9AFN6mFWfqKngTstQnZUKyMGTB6xBwANtrTeT9aV_kl2oYwNuLZTqn_PgSmtie0zeUWmrnUmUH8Hyl7Xy2GiiS00YpsbT-5fXCd-De0eTsND89Hp-8gvuqAxPXEG3D5nJ-Hl_DnfLXsl7M33SwFPDtplX-D1kxHW8 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB21BVW9UD5aWFrASHC0Nms7iV2pVBVlRVVY7aFIvQUn8agRUrLd3bbir_HrmMkm5QS3Hjg7GlmZ8bwZe2YewDuVoM9VHssIdSKN0an0Ng6SoBDViCeCOWzJJtLJxF5cuOka_Op7YbissveJraMum4LvyIcM1XGqrRkNsSuLmJ6Mj2ZXkhmk-KW1p9NYmchZ-HlL6dvi8PSEdP1eqfGn84-fZccwIAuyu6WkaIOSbmuxcBbRFVYHh8FqnZS5j7mFJRhMSgJNLL1JcYRBFWzyOoS8xEiT3HV4kPLQ8rZscNqjQGKSln6P0Nnx7VXUNexE2g4XBJrWSC6OYFY_I83fw9sW5sbb__MPegyPuuBaHK9OwxNYC_VT2PzalQ88gw_nk7GoakFBrwhzLxoUFffHBEGmW_yYNVW9pPXLKq-YhOhAIE-BLkUzF9iEox34di-734WNuqnDCxC5S-OSM3jlnfFJ7KIiIlnoE--09ziA_V4rWecFFtkflQzg7d0ynV9-lPF1aK7pG0o5tbWxSgfwfKX5bLYaNJLRRinhTN3Lfwt_A5uk6ezL6eRsD7ZUa1dcWrQPG8v5dXgFD4ubZbWYv24tVMD3-9b4bwPvJj0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=TNF+in+the+era+of+immune+checkpoint+inhibitors%3A+friend+or+foe%3F&rft.jtitle=Nature+reviews.+Rheumatology&rft.au=Chen%2C+Allen+Y&rft.au=Wolchok%2C+Jedd+D&rft.au=Bass%2C+Anne+R&rft.date=2021-04-01&rft.pub=Nature+Publishing+Group&rft.issn=1759-4790&rft.eissn=1759-4804&rft.volume=17&rft.issue=4&rft.spage=213&rft.epage=223&rft_id=info:doi/10.1038%2Fs41584-021-00584-4&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1759-4790&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1759-4790&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1759-4790&client=summon |